Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 4/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15700831 | 0.92 | CNR1 (0.64) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL12685098 | 0.91 | CNR1 (0.56) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL29744529 | 0.91 | CNR1 (0.56) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL12319236 | 0.85 | CNR1 (0.83) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL12722380 | 0.84 | CNR1 (0.57) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL1604840 | 0.84 | CNR1 (0.57) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL14146316 | 0.83 | CNR1 (0.47) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL14146686 | 0.82 | CNR1 (0.46) | CNR1ALDH1A1FAAHCNR2ALOX12 | |
| SCHEMBL28536043 | 0.82 | TDP1 (0.50) | CNR1ALDH1A1FAAHCNR2 | |
| SCHEMBL1822553 | 0.81 | CNR1 (0.43) | CNR1ALDH1A1FAAHCNR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150504-B2 | Fatty acid guanidine and salicylate guanidine derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20130190327-A1 | BIS-FATTY ACID CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2013-07-25 | — | — | US | disclosed |
| US-20120277305-A1 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| WO-2012115695-A1 | BIS-FATTY ACID CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | WO | disclosed |
| US-20110212958-A1 | FATTY ACID RALOXIFENE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| WO-2011106688-A1 | BIS-FATTY ACID CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212958-A1 | FATTY ACID RALOXIFENE DERIVATIVES AND THEIR USES | ELOVL5, ELOVL3, ELOVL6 | CNR1 2872/4885ALDH1A1 1295/4885FAAH 333/4885 |
| US-20130190327-A1 | BIS-FATTY ACID CONJUGATES AND THEIR USES | FASN, ELOVL1, ELOVL5 | CNR1 2557/4885ALDH1A1 610/4885FAAH 124/4885 |
| US-20120277305-A1 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | SCD, SCD5, FASN | CNR1 2153/4885ALDH1A1 385/4885FAAH 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.